Treating Patients With Melanoma and ALK Alterations With Ensartinib
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effects of the study drug, ensartinib, on the
patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma
with a particular type of abnormality.